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Abstract
Purpose: The chimeric monoclonal antibody (mAb) chDAB4 (APOMAB®) targets the
Lupus associated (La)/Sjögren Syndrome-B (SSB) antigen, which is over-expressed in
tumors but only becomes available for antibody binding in dead tumor cells. Hence,
chDAB4 may be used as a novel theranostic tool to distinguish between responders
and nonresponders early after chemotherapy. Here, we aimed to ascertain which
positron emitter, Zirconium-89 ([89Zr]ZrIV) or Iodine-124 ([124I]I), was best suited to
label chDAB4 for post-chemotherapy PET imaging of tumor-bearing mice and to
determine which of two different bifunctional chelators provided optimal tumor
imaging by PET using [89Zr]ZrIV-labeled chDAB4.
Methods: C57BL/6 J mice bearing subcutaneous syngeneic tumors of EL4 lymphoma
were either untreated or given chemotherapy, then administered radiolabeled
chDAB4 after 24 h with its biodistribution examined using PET and organ assay. We
compared chDAB4 radiolabeled with [89Zr] ZrIV or [124I] I, or [89Zr]Zr-chDAB4 using
either DFO-NCS or DFOSq as a chelator.
Results: After chemotherapy, [89Zr]Zr-chDAB4 showed higher and prolonged mean
(± SD) tumor uptake of 29.5 ± 5.9 compared to 7.8 ± 1.2 for [124I] I -chDAB4. In
contrast, antibody uptake in healthy tissues was not affected. Compared to DFO-NCS,
DFOSq did not result in significant differences in tumor uptake of [89Zr]Zr-chDAB4
but did alter the tumor:liver ratio in treated mice 3 days after injection in favour of
DFOSq (8.0 ± 1.1) compared to DFO-NCS (4.2 ± 0.7).
Conclusion: ImmunoPET using chDAB4 radiolabeled with residualizing [89Zr] ZrIV
rather than [124I] I optimized post-chemotherapy tumor uptake. Further, PET imaging
characteristics were improved by DFOSq rather than DFO-NCS. Therefore, the
radionuclide/chelator combination of [89Zr] ZrIV and DFOSq is preferred for the
imminent clinical evaluation of chDAB4 as a selective tumor cell death radioligand.
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Introduction
Immuno-positron emission tomography/computed tomography (immunoPET/CT) is
attractive clinically for the theranostic purpose of monitoring tumor responses to anti-
cancer therapies because it enables the biodistribution and tumor targeting of mAbs to
be quantified efficiently and with high spatial resolution. To allow time for specific
tumor targeting and blood clearance, which maximizes tumor contrast against non-
tumor background, a positron-emitting isotope with a half-life of 2–4 days is better
suited for labeling mAbs because its physical half-life more closely matches the mAb’s
biologic half-life, which may be days or weeks (van Dongen et al. 2007; Ovacik and Lin
2018). Consequently, the residualizing radiometal [89Zr] ZrIV and the non-residualizing
halogen [124I] I with physical half-lives of 3.27 and 4.18 days, respectively, are exten-
sively used positron-emitters for clinical immunoPET studies (Jauw et al. 2016;
Knowles and Wu 2012; Wright and Lapi 2013) and represent useful scouting matches
for the long-lived therapeutic radionuclides (Verel et al. 2003).
Conventionally, therapy response monitoring relies on categorizing measurements of
predefined changes in either tumor size (Eisenhauer et al. 2009) or tumor FDG uptake
by PET (Wahl et al. 2009; Peacock et al. 2019). However, given that tumor cell death is
a desired endpoint of anticancer therapies, specific and robust in vivo measures are be-
ing intensively investigated preclinically and clinically (Smith and Smith 2012; Zhang
et al. 2019; Zhang et al. 2020). Among the cited in vivo tumor cell death detection tech-
nologies is the mAb DAB4.
The murine DAB4 mAb targets the abundant and ubiquitous nuclear RNA-binding
protein, Lupus associated (La)/Sjögren Syndrome-B (SSB) antigen, which is overex-
pressed in a variety of cancers (Trotta et al. 2003; Sommer et al. 2011; Al-Ejeh et al.
2007a). However, La/SSB becomes available for specific antibody binding in cancer cells
in vitro only after loss of plasma membrane integrity (i.e. in primary or secondary nec-
rotic cancer cells) (Al-Ejeh et al. 2009a; Al-Ejeh et al. 2009b) and in vivo only after
failed tumor clearance of post-apoptotic necrotic cells (Al-Ejeh et al. 2009a; Al-Ejeh
et al. 2014), particularly after DNA-damaging anticancer treatment (Al-Ejeh et al.
2009a; Al-Ejeh et al. 2014). We have previously shown that following radiolabeling of
DAB4 with 111In for tumor imaging (Al-Ejeh et al. 2007b), and 90Y (Al-Ejeh et al.
2009b), 177Lu (Staudacher et al. 2014a) and 227Th (Staudacher et al. 2014b) for tumor
therapy, DAB4 binds with high specificity to dead tumor cells in vivo. Although these
characteristics collectively make DAB4 a dead tumor cell radioligand, the technology of
immunoPET facilitates longitudinal imaging and non-invasive biodistribution studies of
DAB4 in tumor-bearing mice after chemotherapy, hence simulating a clinical scenario.
In this study, rather than murine DAB4, we have used the chimeric version of DAB4,
chDAB4 (APOMAB®) (Staudacher et al. 2018; Staudacher et al. 2020). In this format,
the variable region sequences of murine DAB4 were genetically fused to the constant
region sequences of human IgG1. Also, this human IgG1 Fc domain contains the
K322A mutation, which is known to abrogate C1q binding and therefore complement-
dependent cytotoxicity (Hezareh et al. 2001) (Liapis et al. submitted).
Given that a previous study had directly compared [124I] I or [89Zr] ZrIV labeled ver-
sions of a mAb specific for an internalizing antigen (Cheal et al. 2014) and our own
data had indicated that macrophage-mediated internalization of chDAB4 bound to
dead tumor cells explained the anti-tumor activity of antibody drug conjugates of
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chDAB4 (Staudacher et al. 2018), we wished to compare the biodistribution and tumor
uptake of chDAB4 mAb labeled with these two positron emitters.
The biodistribution of the radiolabeled chDAB4 was investigated using mice bearing
syngeneic subcutaneous implants of the EL4 thymic lymphoblastic lymphoma. The
mice were untreated or treated with DNA-damaging chemotherapy to induce tumor
cell death including post-apoptotic necrosis (Al-Ejeh et al. 2009a; Al-Ejeh et al. 2014).
The EL4 model was chosen because it has been well characterized by us (Al-Ejeh et al.
2009a) and others (Zhao et al. 2001) as a robust model of chemotherapy-induced apop-
tosis. Earlier, we had shown that the extent of post-chemotherapy tumor uptake of
DAB4 predicted longer survival times of tumor-bearing mice, but this demonstration
relied on invasive methods to determine the extent of tumor cell death (Al-Ejeh et al.
2009a). Here, we aim to validate these earlier findings by using chDAB4-immunoPET
as a non-invasive method to show that post-chemotherapy tumor uptake of chDAB4
precedes tumor growth delay, which simulates the clinical scenario.
We also compared the commercially available bifunctional chelator H3DFO-p-
phenyl-isothiocyanate (H3DFO-p-PhNCS or DFO-NCS), which has been used exten-
sively in vivo both in non-clinical and clinical applications to conjugate mAbs for their
subsequent radiolabeling with [89Zr] ZrIV (Dmochowska et al. 2018; Hagens et al. 2018;
Vosjan et al. 2010; Vugts et al. 2017; Dilworth and Pascu 2018), with our newly devel-
oped novel chelator H3DFOSqOEt (DFOSq), which aims to achieve more stable octa-
dentate binding of [89Zr] ZrIV by contributing oxygen molecules to the DFO chelator.
DFOSq is a squaramide ester derivative of H3DFO-p-PhNCS and has previously been
used to radiolabel the anti-HER2 antibody, trastuzumab, with [89Zr] ZrIV. The results
of this study indicated that DFOSq had better stability in vivo and an improved tumor
to background imaging quality than DFO-NCS (Rudd et al. 2016). In addition, recent
data indicate that DFOSq has an improved shelf life compared to DFO-NCS (Berg
et al. 2020). Hence, since we intended to employ DFOSq as the bifunctional chelator
for conjugating chDAB4 in a future clinical study, we wished to test its attributes for
this task in comparison to the industry standard, DFO-NCS.
In the current preclinical immunoPET study of a ligand that preferentially binds dead
tumor cells, we wished to select the optimal positron emitter for imaging tumor cell
death in vivo and to select a bifunctional chelator for [89Zr] ZrIV to take forward in
clinical PET imaging studies. We provide real-time imaging data in favour of chDAB4’s
utility as a selective marker of chemotherapy-induced tumor cell death. Given that ma-
lignant rather than normal healthy tissues were specifically targeted after chemother-
apy, these results support the clinical development of radiolabeled chDAB4 as a
theranostic imaging agent with the potential to deliver dosimetric data in a clinical
setting.
Material and methods
Cell culture and antibodies
EL4 murine thymic lymphoma cells were obtained from American Type Cell Culture
(ATCC) and cultured in RPMI1640 containing 10% fetal calf serum (FCS) (Bovogen Bi-
ologicals, Victoria, Australia) with streptomycin and penicillin (Sigma-Aldrich). Cells
were negative for mycoplasma contamination using MycoAlert® Mycoplasma Detection
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Kit (Lonza, Basel, Switzerland). The chimeric version of DAB4 (chDAB4) was created
at CSIRO Molecular and Health Technologies (Parkville, VIC, Australia) by genetically
fusing the variable region sequences of murine DAB4 to the constant region sequences
of human IgG1. Using the CHO-XL99 expression system, a stable producer cell line of
chDAB4 was manufactured at the National Biologics Facility, Australian Institute for
Bioengineering and Nanotechnology, University of Queensland (Brisbane, QLD,
Australia) (Staudacher et al. 2018; Staudacher et al. 2020).
La ELISA and Lindmo binding assay
The binding of chDAB4 to the previously published La/SSB epitope (Tran et al. 2002)
was performed as described (Staudacher et al. 2018). The Lindmo binding assay
(Lindmo et al. 1984) was used to determine the immunoreactive fraction (IRF) of radi-
olabeled preparations of chDAB4. EL4 lymphoma cells were fixed and permeabilized
using 10% neutral buffered formalin and methanol as previously described (Al-Ejeh
et al. 2009a; Al-Ejeh et al. 2009b), resuspended in PBS with 1% FCS and serially diluted
in duplicate 0.5 mL aliquots at cell numbers ranging from 5.5 × 107 to 3.4 × 106. Then
0.5 mL of 50 ng/mL radiolabeled antibody in 1% FCS was added to the cell suspensions.
After incubation at 4 °C overnight, cells were centrifuged at 300 g, and 0.5 mL of the
supernatant from each sample was placed in a separate tube and the radioactivity in
the cell pellets and the supernatant was measured using the Hidex Automatic Gamma
Counter.
Conjugation and radiolabeling of chDAB4 with [89Zr] ZrIV and [124I]I
chDAB4 was conjugated to the bifunctional chelator H3DFO-p-PhNCS (DFO-NCS)
(Macrocyclics, Texas, USA) as previously described (Vosjan et al. 2010; Holland et al.
2010). The bifunctional chelator H3DFOSqOEt (DFOSq), which is a squaramide ester
derivative of DFO, was synthesized and conjugated to the antibody as described (Rudd
et al. 2016). The chelator to antibody ratio was determined by Electro Spray Ionisation
Mass Spectrometry (ESI-MS) on an Agilent 6510 ESI-TOF LC/MS Mass Spectrometer
(Agilent, California USA) and was 1.3:1 for DFO-NCS and 2.55:1 for DFOSq. All data
were acquired and reference mass corrected via a dual-spray electrospray ionisation
(ESI) source. [89Zr] ZrIV oxalate was produced via proton irradiation of a 89Y target on
a PETtrace 880 cyclotron (GE Healthcare) and purified on an Alceo purification system
(Comecer, Italy) in the Molecular Imaging and Therapy Research Unit (MITRU) of the
South Australian Health and Medical Research Institute (SAHMRI) as described (Hol-
land et al. 2009) and the immunoconjugates were radiolabeled as described previously
(Vosjan et al. 2010). Briefly, while gently shaking at room temperature, 90 μL of 2M
Na2CO3 was added to 120MBq of [
89Zr] ZrIV oxalate solution and incubated for 3 min
at room temperature, 300 μL of 0.5 M HEPES buffer and 1mg of chDAB4 conjugated
to DFO-NCS in 0.25M NaCO3 were then added, followed by an additional 700 μL of
0.5M HEPES buffer (pH 7.1) and incubated for 1 h at room temperature.
Sodium Iodide [124I] I in 0.02M NaOH solution was purchased from Austin Health
(Heidelberg, Vic, Australia). Conjugation of [124I] I to chDAB4 was performed using
Pierce® Iodination beads (Thermo Scientific, Massachusetts, USA). Briefly, iodination
beads were washed in PBS and allowed to dry before being added to 100 μL PBS and
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100MBq of [124I] I and incubated for 5 min at room temperature. One milligram of
chDAB4 was added and incubated for 10 min at room temperature before the solution
was removed from the beads.
Both [89Zr] ZrIV- and [124I] I-labeled antibodies were buffer-transferred and concen-
trated using Amicon® 50 kDa cut-off centrifugal filter devices (Millipore Massachusetts,
USA) and resuspended in PBS for injection. Instant thin layer chromatography (ITLC)
confirmed that < 1% free radionuclide was present in the preparations.
Animal tumor inoculations and treatments
All animal experiments were approved by the SAHMRI Animal Ethics Committee
(Adelaide, Australia), and were conducted following institutional ethical guidelines. Fe-
male C57BL/6 J mice 6–10 weeks old were inoculated subcutaneously in the right flank
with 106 syngeneic EL4 cells in PBS. Mice in the untreated group were injected with
tumor cells 3 days later. This method of staggering tumor growth allows size-matched
tumors to be compared at the time of imaging of the animals, thus mimicking clinical
practice (Al-Ejeh et al. 2009a; Al-Ejeh et al. 2009b). Electronic calipers were used to
measure the dimensions of the tumor, the volume of which was calculated as (a2 × b)/2,
where a is the shortest diameter and b is the longest diameter of the tumor. Mice with
7-day old tumors were given intraperitoneal injections of 25 mg/kg cyclophosphamide
and 19mg/kg etoposide (Day 0). The following day mice were given intravenous injec-
tions with 5MBq/50 μg of [124I] I- or [89Zr] ZrIV-labeled chDAB4 using the commer-
cially available chelator DFO-NCS. To compare the different bifunctional chelators, 6
MBq/18 μg of [89Zr] ZrIV-labeled chDAB4, which had been conjugated either with
DFO-NCS or DFOSq, was given intravenously.
Stability of radiolabeled antibodies
To test in vitro stability of the radiolabeled antibodies, 500 kBq of the radiolabeled anti-
body was incubated in FCS at 37 °C for 6 days following radiolabeling. Samples were
analyzed by ITLC using 20 mM citric acid (pH 5) as the solvent.. ITLC strips were cut
in half and analyzed using the Hidex gamma-counter to measure the amount of free
[89Zr] ZrIV or [124I] I present.
Animal imaging
For PET imaging, mice were gas-anesthetized with isoflurane (Veterinary Companies of
Australia, NSW, Australia) and scanned for 10 min using the Albira Si PET-SPECT
small animal scanner (Bruker Biospin GmbH, Valencia, Spain). Regions of interest were
manually drawn around the tumor using PMOD® software (PMOD Technologies,
Switzerland) and the tumor uptake determined as the injected dose per gram (%ID/g)
following decay correction as calculated by the PMOD software. Area under-curve
(AUC) values were calculated from activity curves, which were generated over 8 days.
At the end of the experiment, organs were removed, weighed and the accumulation
of [89Zr] ZrIV and [124I] I was measured using the Hidex gamma-counter. Radioactivity
in the organs was normalized to organ weight and calculated as the percentage of
radioactivity per gram over the radioactivity of the injected dose of the radiolabeled
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chDAB4 (%ID/g). Tumor to organ ratios were calculated by dividing the %ID/g values
for tumor by those for blood, bone or liver.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (v8.0) software. Comparison
of two groups was performed by two-tailed t-test or intergroup comparisons made by
two-way analysis of variance (ANOVA). Data are shown as the mean ± standard devi-
ation (SD). Statistical significance was reached when p < 0.05, with * representing p <
0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
Results
Stability and antigen binding of radiolabeled chDAB4 in vitro
Radiolabeling of DFO-NCS-conjugated chDAB4 with [89Zr] ZrIV or radiolabeling of in-
tact chDAB4 with [124I] I resulted in specific activities of ≥100MBq/mg with < 1% free
radionuclide in each preparation. ELISA was used to compare binding to the La-
derived peptide epitope of unconjugated chDAB4, DFO-conjugates of chDAB4, and
radiolabeled versions of the chDAB4 conjugates. All antibodies bound with high avidity
to the La peptide with dissociation constants (Kd ± SEM) of 32.1 pmol/L ± 4.8 for
chDAB4, 33.8 pmol/L ± 4.9 for DFO-NCS-chDAB4, 38.2 pmol/L ± 7.3 for [89Zr]Zr-
DFO-NCS-chDAB4 and 46.2 ± 7.7 for [89Zr]Zr-DFOSq-ch-DAB4 (Fig. 1a. top panel). In
a separate ELISA experiment, we compared the Kd values for [124I]I-and [89Zr]ZrIV-
radiolabeled chDAB4 mAbs. The Kd (± SEM) values were 4.9 ± 1.0, 10.2 ± 2.9, 10.8 ±
3.1 and 16.9 ± 5.5 pmol/L for chDAB4, DFO-NCS-chDAB4, and chDAB4 radiolabeled
with [124I] I and [89Zr] ZrIV, respectively (Fig. 1a. bottom panel). The immunoreactive
fraction (IRF) was also determined for each form of chDAB4 by the Lindmo assay, with
the IRF (± SD) for [89Zr]Zr-DFO-NCS being 78.5 ± 9.1%, 74.6 ± 0.8% for [89Zr]Zr-
DFOSq-ch-DAB4 and 75.4 ± 10.1% for [124I]I-chDAB4, demonstrating that the conjuga-
tion and radiolabeling procedures had little effect on the immunoreactivity of the
chDAB4 radioconjugates (Fig. 1b).
Radiolabeled antibodies were stable in FCS at 37 °C during a 6-day period in vitro:
free [89Zr] ZrIV was detected in the range of 0.5–10.9% and free [124I] I was detected in
the range of 1.4–6.3% (Fig. 1c).
The chDAB4 mAb radiolabeled with [89Zr] ZrIV binds to dead tumor cells after
chemotherapy in vivo
As seen in previous studies (Al-Ejeh et al. 2009a; Al-Ejeh et al. 2014; Staudacher et al.
2014a; Staudacher et al. 2014b; Staudacher et al. 2018), EL4 tumors hosted by syngen-
eic mice were chemo-responsive resulting in significant reductions in tumor size deter-
mined by caliper measurements and ex vivo tumor weights (Fig. 2a and b). As
expected, no significant differences were observed in tumor growth rates between mice
receiving [89Zr]ZrIV- or [124I]I-labeled antibodies alone or after chemotherapy, indicat-
ing that the radionuclides per se had no appreciable therapeutic effect (Fig. 2).
Next, we examined the biodistribution of [89Zr]Zr-chDAB4 and [124I]I-chDAB4 in
tumor bearing mice (Fig. 3). Tissue biodistribution showed significant blood and
lung accumulation of [124I] I activity in treated mice (mean %ID/g ± SD; 18.3 ± 4.0
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and 8.2 ± 3.1) compared to untreated mice (8.8 ± 2.9 and 3.5 ± 1.2), respectively.
Notwithstanding the availability of [124I]I-chDAB4 in serum, relatively little [124I]I-
chDAB4 had accumulated in tumors at the end of the experiment (Fig. 3b), al-
though PMOD analysis shows significantly more tumor accumulation of [124I]I-
chDAB4 in treated mice over the course of the experiment (Fig. 3c). In contrast,
in mice administered [89Zr]Zr-chDAB4, significant tumor accumulation of tracer
after chemotherapy was evident (± SD): 19.9 ± 6.7 vs 29.4 ± 5.8%ID/g for untreated
vs treated mice (Fig. 3b), with no significant differences in normal tissues.
Fig. 1 Immunoreactivity and stability of conjugates and radioconjugates of chDAB4. Binding of
chDAB4 to the La peptide was measured by ELISA and is equivalent for DFO-NCS-chDAB4, [89Zr]Zr-
DFO-NCS-chDAB4, [89Zr]Zr-DFOSq-chDAB4, and [124I]I-labeled chDAB4 (n = 3) (a). Lineweaver-Burk plots
show values for the immunoreactive fraction (IRF) determined by the Lindmo assay. The IRF values for
the [89Zr]Zr-labeled DFO-conjugates of chDAB4, [89Zr]Zr-DFO-NCS and 89Zr-DFOSq, and for [124I]I-
labeled APOMAB (124I), were 78.5%, 74.6% and 75.4%, respectively (b). The chDAB4 mAb radiolabeled
with [89Zr] ZrIV or [124I] I is stable over 6 days in FCS at 37 °C as determined by ITLC (c). All data
points are means ± SD
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Furthermore, PMOD analysis demonstrated that chemotherapy resulted in incre-
mental tumor accumulation of [89Zr]Zr-chDAB4 (Fig. 3c).
Using decay-corrected PMOD data over the course of the experiments, we estimated
that cumulative exposure of post-chemotherapy tumors to the activity (%ID/g ± SD) of
[89Zr]Zr-chDAB4 compared to that of [124I]I-chDAB4 was 75.9 ± 14.3%ID/g per hour
vs 40.1 ± 5.2%ID/g per hour, respectively.
In summary, these data indicate that the [89Zr] ZrIV label residualizes in tumors in
contradistinction to the [124I] I label.
Comparison of biodistribution of chDAB4 conjugated with DFO-NCS or DFOSq
Next, we compared the two different types of bifunctional chelator, DFO-NCS and
DFOSq, for the labeling of chDAB4 with [89Zr]ZrIV. Representative PET images are
shown in Fig. 4a. Using organ assays to measure physical γ-counts, tumor accumulation
of [89Zr]Zr-chDAB4 was significantly greater in treated mice compared to untreated
mice regardless of whether chDAB4 was conjugated with DFO-NCS or DFOSq (Fig. 4a
and b). On Day 3, mean tumor uptake (%ID/g ± SD) of [89Zr]ZrIV-labeled DFO-NCS-
and DFOSq-conjugates of chDAB4 was 19.3 ± 6.6 and 22.5 ± 4.8 in treated mice vs
9.5 ± 2.5 and 10.5 ± 2.4 in untreated mice, respectively. On Day 8, mean tumor uptake
(%ID/g ± SD) was 30.0 ± 13.2 and 32.4 ± 19.3 in treated mice vs 6.5 ± 4.9 and 6.9 ± 2.7
in untreated mice, respectively. Although we did not observe any significant differences
in tumor uptake of [89Zr]Zr-chDAB4 using either chelator in separate studies on Days
3 or 8 we did observe significantly accelerated blood clearance of the [89Zr]Zr-labeled
DFOSq-conjugate of chDAB4 compared to the DFO-NCS-conjugate on Day 3 in un-
treated mice (14.8 ± 3.4 vs 9.5 ± 4.1%ID/g ± SD) (Fig. 4c). On the other hand, image
processing and volume of interest (VOI) analysis using PMOD software over the 8-day
scanning period showed significantly greater tumor uptake of [89Zr]Zr-chDAB4 in
Fig. 2 Effects of chemotherapy on tumor size in mice administered different radioconjugates of chDAB4.
Tumor growth curves and tumor weights (n = 5) testing different radiolabels (a) or different bifunctional
chelators (b). All data points are means ± SD
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untreated mice using the DFOSq-conjugate compared to the DFO-NCS-conjugate
(Fig. 4b).
It is important to note that organ assays did not demonstrate any significant differences
in normal tissue uptake including bone of [89Zr]Zr-chDAB4 irrespective of chemotherapy
use or the type of bifunctional chelator (Fig. 4c). However, by comparing the physical γ-
counts in the organ assays done on Day 3, we calculated the ratio of %ID/g in tumor to
that in blood, bone (femur) or liver for each type of chelator. Compared to the standard
DFO-NCS-conjugate, there was a significantly higher tumor:tissue ratio for bone and liver
for the DFOSq-conjugate (Fig. 4d). The average tumor to bone ratio for the DFOSq-
conjugate was 15.0 vs 5.3 in treated vs untreated mice, which suggests that the DFOSq-
conjugate may be more stable and thus less likely to release [89Zr] ZrIV, which targets
bone (Fischer et al. 2013). The average tumor to liver ratios for the DFOSq-conjugate
were 8.0 vs 2.8 in treated vs untreated mice and 8.0 vs 4.2 in treated mice that received
the DFOSq-conjugate vs the DFO-NCS-conjugate. These results suggest that the DFOSq-
conjugate of [89Zr]Zr-chDAB4 may yield better imaging quality than the DFO-NCS-
conjugate. By Day 8, no significant differences were observed in the tumor: normal tissue
ratios irrespective of the type of chelator with average tumor to liver ratios for the
DFOSq-conjugate of 4.5 vs 8.6 in treated vs untreated mice and 9.3 vs 8.6 in treated mice
that received the DFOSq-conjugate vs the DFO-NCS-conjugate.
Fig. 3 Effect of chemotherapy on tumor and normal tissue uptake of different radioconjugates of chDAB4.
Representative whole-body PET images of a single mouse from each group during the course of the
experiment are shown. Color scale indicates relative extent of tissue uptake of radioactivity. Asterisks in
black at Day 5 time point indicate blood pool. Arrows in white at Day 8 time point indicate tumors in right
flank of each mouse (n = 5) (a). Ex vivo biodistribution of the [89Zr]ZrIV- and [124I]I-labeled chDAB4 on Day 8
was measured using the HIDEX counter (b). Tumor uptake of [124I]I- and [89Zr]ZrIV-labeled chDAB4 during
the course of the experiment was quantified and expressed as Percent Injected Dose per gram (%ID/g)
using PMOD® software (c). All data points are means ± SD
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Fig. 4 Effects of chemotherapy on tumor and normal tissue uptake of [89Zr]ZrIV-labeled chDAB4 using
different bifunctional chelators. Representative whole-body PET images of a single mouse from each group
(n = 5) during the course of the experiment are shown. Color scale indicates relative extent of tissue uptake
of radioactivity. Arrows in white at Day 8 time point indicate tumors in right flank of each mouse (a). Tumor
uptake of the [89Zr]ZrIV-labeled antibodies during the course of the experiment was quantified and
expressed as Percent Injected Dose per gram (%ID/g) using PMOD® software (b). The biodistribution of
[89Zr]ZrIV-labeled DFO-NCS (DFO) and DFOSq conjugates of chDAB4 was measured using the HIDEX
counter in tumor and organs taken from mice on Days 3 and 8 (c). On Day 3, %ID/g derived from physical
γ-counts measured in different organs were expressed as a ratio for tumor to blood, tumor to bone, or
tumor to liver (d). All data points are means ± SD
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Discussion
To determine the preferred positron emitter for the planned clinical PET detection of
chemotherapy-induced tumor cell death and to gain a better understanding of the pro-
cessing of radiolabeled chDAB4 within tumors, we labeled chDAB4 with residualizing
[89Zr] ZrIV or non-residualizing [124I] I. We observed pronounced tumor uptake and
retention of [89Zr]ZrIV-labelled chDAB4 compared to [124I]I-labelled chDAB4, particu-
larly when given after chemotherapy. Interestingly, these results match those seen by
others who used internalizing antibodies labeled with [89Zr] ZrIV and [124I] I, and
showed that [89Zr] ZrIV is trapped within the cells whereas [124I] I is released from cells
(Wu 2014; Mendler et al. 2015; Fung et al. 2016; Deri et al. 2013). For example, in a
pairwise comparison of [124I]I- and [89Zr] ZrIV labeled versions of girentuximab, which
is an internalizing mAb specific for carbonic anhydrase 9, both antibody preparations
had equivalent in vivo tumor uptake kinetics in a xenograft model of human clear cell
renal cell carcinoma but only [89Zr]ZrIV-girentuximab resulted in prolonged tumor re-
tention (Cheal et al. 2014).
However, given that the La/SSB target antigen of the radiolabeled chDAB4 mAb is
revealed preferentially in dead tumor cells in vivo (Al-Ejeh et al. 2009a; Al-Ejeh et al.
2014; Staudacher et al. 2014a; Staudacher et al. 2014b; Staudacher et al. 2018), the anti-
body radioconjugate will not be further processed unless it is by a non-targeted viable
cell type. We hypothesize that tumor-associated macrophages (TAMs), which are
highly abundant within tumor necrotic regions (Murdoch et al. 2004) and further
enriched after chemotherapy (Staudacher et al. 2018), engulf and process [89Zr]Zr-
chDAB4 bound dead tumor cells.
This TAM-mediated internalization of chDAB4-bound tumor cells, particularly after
chemotherapy, may thus enable [89Zr] ZrIV to be residualized and would explain why sig-
nificantly more [89Zr]Zr-chDAB4 was detected in the tumor compared to [124I]I-chDAB4.
On the other hand, as a non-residualizing radionuclide, 124I would be released extracellu-
larly and may thus account for the higher 124I activity found in blood and lung (as blood
pool) after chemotherapy. As we described for macrophage-mediated processing of DAB4
antibody drug conjugates in the syngeneic Lewis lung carcinoma model in which C57BL/
6 J mice bear subcutaneous tumors of LL2 cells (Staudacher et al. 2018), TAM-mediated
phagocytosis of [89Zr]Zr-chDAB4-bound dead tumor cells may account for the post-
chemotherapy finding of augmented tumor uptake of [89Zr]Zr-chDAB4 in the EL4 lymph-
oma model. This EL4 model is well-characterized and the La/SSB-specific mAb binds spe-
cifically, rapidly, avidly, and irreversibly to the La/SSB target antigen in post-apoptotic
necrotic EL4 tumor cells (Al-Ejeh et al. 2009a; Al-Ejeh et al. 2009b).
Work published by Donnelly et al. compared their novel chelator DFOSq to DFO-
NCS using the HER2-targeting antibody, trastuzumab (Rudd et al. 2016). In mice bear-
ing HER2-positive human ovarian cancer and breast cancer xenografts, as measured by
ratios of tumor to background, bone and liver and by tumor SUVmax measurements ac-
cording to type of chelator, [89Zr]Zr-DFOSq–trastuzumab showed improved PET im-
aging and radiolabeling efficiency over DFO-NCS, thus warranting further
investigation. Although we consistently observed numerically higher %ID/g values over
the course of the experiment for tumor uptake of [89Zr]Zr-DFOSq-chDAB4 compared
to [89Zr]Zr-DFO-NCS-chDAB4, either by organ assay or PMOD analysis, statistical sig-
nificance was not reached. However, 3 days after chemotherapy and before tumor
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growth delay is evident (Fig. 3) we did identify improved tumor to normal tissue ratios
for [89Zr]Zr-DFOSq-chDAB4 compared to [89Zr]Zr-DFO-NCS-chDAB4. These data in-
dicate that the post-chemotherapy tumor uptake of [89Zr]Zr-DFOSq-chDAB4 signifi-
cantly exceeded its uptake in both bone and liver, unlike [89Zr]Zr-DFO-NCS-chDAB4.
As an example of determining optimal tumor to nontumor ratios, the liver has been
the most studied and extensively used reference region for clinical whole-body FDG-
PET (Hofheinz et al. 2016).
Contrary to other [89Zr] ZrIV antibody radiolabeling studies [29, 30] [89Zr]Zr-chDAB4
showed high stability in vitro and the relatively low bone uptake compared to tumor
uptake also indicated in vivo stability over 7 days. PET quantification imaging and bio-
distribution data indicate free [89Zr] ZrIV accumulation in the bone is minimal when
compared to radiolabeled antibody uptake in the tumor. Antibody accumulation in
healthy tissues was further reduced when injected amounts of radiolabeled chDAB4
were reduced from 50 μg (Fig. 3) to 18 μg (Fig. 4), leading to higher tumor to back-
ground contrast, in agreement with specific and saturable in vivo tumor binding of the
antibody (Al-Ejeh et al. 2007b).
Conclusion
Here, we show that chDAB4 labeled with a positron-emitting radionuclide is stable
both in vitro and in vivo and enables whole-body live animal PET imaging of
chemotherapy-induced tumor cell death, which subsequently manifests as tumor
growth delay. Consequently, immunoPET with chDAB4 might be employed clinically
to discern in whom the cancer will shrink or stabilize soon after a first course of DNA-
damaging chemotherapy. However, the ability of chDAB4 to serve this purpose effect-
ively depends on the specific positron-emitter used. ImmunoPET with [124I]I-chDAB4
displays low tumor uptake and could not adequately discriminate the effect of chemo-
therapy on tumor cell death. In contrast, immunoPET with [89Zr]Zr-chDAB4 shows
high and persistent tumor accumulation of the radiolabel after chemotherapy, presum-
ably because of the residualizing properties of [89Zr] Zr with or without its chelator.
Moreover, we found that [89Zr]Zr-labeling of the chDAB4 immunoconjugate employ-
ing the squaramide ester form of DFO rather than commercially available DFO-NCS
form resulted in superior imaging characteristics, which may be better suited to its ap-
plication in clinical immunoPET. In this respect, we have commenced an IRB-approved
phase 1 clinical theranostic study of [89Zr]Zr-DFOSq-chDAB4 in patients with ad-
vanced lung and ovarian cancer after they receive their first cycle of platinum-based
chemotherapy (Australian and New Zealand Clinical Trials Registry No. ACTR
N12620000622909). Using this radiotheranostic agent to visualize and quantify
chemotherapy-induced tumor cell death may enable immunoPET to distinguish che-
mosensitive from chemoresistant types of cancer.
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